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The Guild’s proposals for improved access to 
health data for research purposes 
Introduction 
In February 2020, the European Commission 
presented the European Data Strategy. 1  Its 
ambition is to give a strong impetus to the 
emergence of a single market for data and 
data-driven society and economy in Europe. 
The strategy calls, to that end, for the creation 
of “common data spaces in strategic sectors 
and domains of public interest”. The European 
Commission’s proposal for a Digital Govern-
ance Act2 published in November 2020 fleshes 
out this idea. The common data spaces aim to 
increase the availability of data for reuse by re-
moving barriers to data exchange and encour-
aging data sharing notably on altruistic 
ground. Both the European Data Strategy and 
the proposal for a Digital Governance Act rec-
ognize the importance of dedicating one of 
these common data spaces to health data.  
The European Commission’s proposal for a Eu-
ropean Health Data Space pursues three 
 
1 “A European strategy for Data”, COM(2020) 66 final. 
2 Proposal for a regulation on European data governance (Data 
Governance Act), COM(2020) 767 final. 
objectives: to facilitate (cross-border) sharing 
of health data either for improving health care 
(primary purpose) or for research and policy 
purposes (secondary purposes); to remove ob-
stacles to the free movement of digital health 
services; and to support the development and 
deployment of artificial intelligence services. In 
its proposals for the Pharmaceutical Strategy 
for Europe,3  The Guild has already acknowl-
edged the idea of a European Health Data 
Space (EHDS) and recommends that this space 
should provide a “clear legal framework for en-
abling cross-border sharing of sensitive data, 
and the merging of data from multiple coun-
tries”. The present paper further elaborates on 
this recommendation. First, it reminds us of the 
importance of access to health data for medi-
cal research. It then describes the main chal-
lenges that impede the reuse of health data for 
research purposes. Finally, it formulates recom-
mendations for the European Health Data 
Space and other EU actions.  
3 The Guild (2020) Proposal for the Pharmaceutical Strategy 
for Europe. The Guild of European Research-Intensive Uni-
versities and Bern Open Publishing. DOI: 10.7892/bo-
ris.146527 
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1. The importance of access to health 
data for research purposes 
Access to health data is crucial for medical re-
search. A large volume of data is more likely to 
provide compelling and robust evidence. The 
improvement of disease diagnostic techniques 
and treatments and of preventive and health 
promoting strategies also relies on the combi-
nation of diverse data. The cross-border ex-
change of data in the context of multi-national 
clinical trials ensures that conclusions are valid 
for different groups of people, and avoids any 
misleading focus on the idiosyncrasies of spe-
cific populations, e.g. in terms of genetics and 
of social and environmental determinants.4 Re-
searchers must be allowed also to tap into non-
clinical and non-health data. The combination 
of diverse data is essential to enable research-
ers better to elucidate the determinants of 
health, and may therefore make a significant 
contribution to the development of more ef-
fective health diagnostics and treatment, to the 
reduction of health inequalities, and to shifting 
society towards prevention.  
 
2. Challenges facing the (re)use of 
health data for research purposes 
The General Data Protection Regulation 
(GDPR)5 and the interpretation of some of its 
provisions impose limitations on the sharing 
and reuse of health data for research purposes. 
 
4 ALLEA, EASAC & FEAM (2021) International Sharing of Per-
sonal Health Data for Research. DOI: 10.26356/IHDT. 
5 Regulation (EU) 2016/679 of the European Parliament and of 
the Council of 27 April 2016 on the protection of natural per-
sons with regard to the processing of personal data and on the 
free movement of such data. 
6 European Parliamentary Research Service (2019) How the 
General Data Protection Regulation changes the rule for 
The GDPR provides a regulatory framework for 
the protection of personal data. It prohibits the 
processing of sensitive data, whose misuse 
may affect individuals. Some exemptions to 
these rules were intended to avoid any stifling 
of research and innovation activities, especially 
in health. However, the European Parliamen-
tary Research Service acknowledged that the 
(medical) research community still viewed the 
GDPR as a barrier to research in 2019.6  
The Guild similarly notes that it is still unclear 
how and to what extent the exemptions for re-
search in the GDPR apply to health research, as 
there has so far been little case law on this 
topic. For instance, since it is uncertain how 
cloud-based infrastructures such as the EHDS 
and cloud providers could ensure compliance 
with GDPR, the potential of the cloud for the 
storage and sharing of health data is not yet 
fully exploited. Moreover, the Member States 
do not share the same interpretation of the 
GDPR rules and their applications, hence there 
is high heterogeneity across EU and EEA Mem-
ber States in their policies for reuse and sharing 
of data.7  Because of these uncertainties and 
the lack of cross-border harmonization, re-
search actors avoid sharing health data across 
borders and/or reusing health data for re-
search purposes in order to ensure their com-
pliance with GDPR rules.  
Some provisions in the GDPR create obstacles 
to health research too. It is, for instance, widely 
understood that data subjects must give, in 
some instances, their explicit consent to the 
transfer of their personal data. As this consent 
must be given for specific research projects, it 
scientific research, Scientific Foresight Unit (STOA) of the Euro-
pean Parliament. DOI: 10.2861/17421  
7 European Commission (2021) Assessment of the EU Member 
States’ rules on health data in the light of GDPR. Luxembourg: 
Publications Office of the European Union. DOI: 
10.2818/546193 
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does not allow for the reuse of the data in other 
– even relevant – research projects. The Guild 
notes that the GDPR rules are interpreted as in-
troducing the obligation to provide separate 
and specific consent for each data processing 
operation. This requirement, although under-
standable and desirable in many respects, is 
not practical to implement in many cases. The 
result is that data reuse is not allowed, not even 
for public health reasons or in presence of clear 
social benefits.  
In contrast with pseudonymized data, anony-
mized data do not relate to identified or iden-
tifiable natural people and do not therefore 
need to comply with the GDPR data protection 
rules. However, health data such as genome 
sequences are impossible or very difficult to 
anonymize. The combination of health data 
also increases the possibility of tracing back to 
the individual subjects. Therefore, their anony-
mization is not a sensible solution for allowing 
the (cross-border) exchange of health data. It is 
also worth noting that anonymization reduces 
the value of data in the context of medical re-
search, as it would imply removing some varia-
bles that could potentially offer useful insights. 
 
3. Suggested actions 
In light of the aforementioned challenges, The 
Guild recommends that the European Com-
mission pay attention to the following points 
when shaping the EHDS: 
• Clarify GDPR provisions, especially those 
introducing exemptions for the use and 
processing of personal data for the pur-
pose of (medical) research. It is crucial that 
the European Commission reduces 
 
8 European Data Protection Board (2020) Guidelines 03/2020 on 
the processing of data concerning health for the purpose of sci-
entific research in the context of the COVID-19 outbreak. 
existing uncertainties about the interpreta-
tion of GDPR rules. For instance, the Euro-
pean Data Protection Board (EDPB)8 has al-
ready highlighted that the GDPR does not 
define explicitly what “processing for the 
purpose of scientific research” entails. The 
Guild calls, in this respect, for a broad but 
clear definition encompassing scientific re-
search, technological developments, fun-
damental research and privately funded re-
search, so that exemptions to the GDPR 
rules “for scientific research” can apply to 
them. Overall, clarifications must aim at a 
harmonized interpretation of the GDPR 
and its provisions regarding the conditions 
to be met for the sharing and processing of 
personal health data at the EU level. It is 
also important that these clarifications re-
duce the administrative burdens on re-
searchers and their universities induced by 
the obligation to demonstrate their compli-
ance with GDPR.  
• Adapt the degree of protection to the de-
gree of sensitivity of the data. The concept 
of health data encompasses different types 
of data which, even though they are not all 
sensitive, are all covered by the same level 
of protection. The GDPR provides a broad 
definition of “data concerning health” as 
“personal data related to the physical or 
mental health of a natural person, including 
the provision of health care services, which 
reveal information about his or her health 
status” (article 4(15)). In 2020, the EDPB9 re-
minded us that data concerning certain as-
pects of health deserve a higher protection 
than other types of data, and that data 
combined with health data should be also 
considered health data and be equally pro-
tected. While acknowledging the need to 
9 Ibid. 
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protect the privacy of patients and, more 
broadly, any individual, The Guild contends 
that all health data – according to the defi-
nition above – are not equally sensitive. For 
instance, the processing of data such as 
blood pressure, heart rate or haemoglobin 
levels may not present the same level of 
threat to individuals as the processing of 
genetic data. Therefore, the European 
Commission should consider whether all 
health data deserve the same level of pro-
tection or whether the degree of protection 
must depend on the sensitivity of the data. 
• Revise the rules relative to patients’ con-
sent to data processing and transfer. 
o The Guild welcomes the provisions in the 
European Commission’s proposal for a 
Digital Governance Act introducing the 
concept of ‘data altruism’ and the Euro-
pean data altruism consent form (Article 
22) for a higher harmonization across 
Member States. Data altruism must nev-
ertheless have a larger scope and en-
compass also data transfer in order to fa-
cilitate multi-country clinical studies and 
cross-border data-driven medical re-
search. If adopted, the concept of data 
altruism may nevertheless apply only to 
data collected after the entry in force of 
the Data Governance Act. The Guild is in-
viting the European Commission to find 
solutions, e.g. an amnesty, to allow the 
safe exploitation of data collected before 
that date.  
o The Guild encourages the European 
Commission to support the development 
and uptake of dynamic consent systems. 
Online platforms could indeed facilitate 
 
10 Budin-Ljøsne, I., Teare, H.J.A., Kaye, J. et al. (2017) “Dy-
namic Consent: a potential solution to some of the challenges 
of modern biomedical research”. BMC Medical Ethics 18, 4. 
DOI: 10.1186/s12910-016-0162-9 
informed and personalized consent while 
improving communication between re-
searchers and individual subjects and al-
lowing the latter to give their consent to 
new research activities that were not 
foreseen in the original consent.10  
o Alternative systems, which offer a safe 
space for the processing and/or transfer 
of health data for research purposes 
without relying on the formal individuals’ 
specific consent, may deserve public 
support and favourable enabling condi-
tions too. They can build on initiatives 
such as the Data Safe Havens in Scot-
land11 or the citizen cooperatives in Swit-
zerland which allow for the processing of 
personal data under the control of the 
subject individuals.12  
• Consider data federation aspects allowing 
for federation to different levels: national 
nodes, individual institutes and individual 
citizens. The European Health Data Space 
should support the development of effi-
cient tools for federated analysis, and the 
implementation of data visiting solutions in 
which queries and algorithms travel to the 
data, instead of having a centralized ap-
proach where data travels to the algorithm. 
This will require the development of a legal 
clarification on how to interpret the GDPR 
in such a data visiting paradigm. 
• Support the development of privacy en-
hancing technologies. EU funding instru-
ments, such as Horizon Europe or the 
EU4Health programme, should finance re-
search & development projects aimed at 
the further development of technologies 
and methodologies for improving the 
11 www.nhsresearchscotland.org.uk/research-in-scot-
land/data/safe-havens 
12 For instance: www.midata.coop 
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quality of synthetic data created on the ba-
sis of real-world data. Another avenue for 
technological progress is the development 
of solutions to enable the export of main-
tained time-series data. The transfer of 
data requires better interoperability be-
tween data storage infrastructures, hence 
the need for further support to the creation 
and implementation of standardized proto-
cols for organizing data in interoperable 
units (e.g., HL7-FHIR). These technological 
advancements must nevertheless be cou-
pled with the development of legal clarifi-
cations, e.g. on how the GDPR rules are ap-
plicable to privacy enhancing technologies 
(if any). 
• Develop an approach based on risk-bene-
fit/value assessment. In the medical device 
industry, there are tools for value/benefit 
assessment and others for risk assessment 
and management. Similarly, the GDPR in-
troduced the concept of Data Protection 
Impact Assessment (DPIA) to identify and 
minimize privacy-related risks in data pro-
cessing activities. Risk analysis is used to 
identify risks and reduce them to the lowest 
reasonably practicable level, while consid-
ering that the residual risk is never zero. 
Balancing benefits/values and risks is cer-
tainly a complex task. It implies defining cri-
teria and thresholds on the acceptance of 
the residual risk. Decisions on allowing the 
processing and transfer of health data 
should not consider exclusively technical 
and legal parameters. There is instead the 
need for a well-defined decision-making 
process that needs to integrate both tools 
for risk-benefit/value assessment and tools 
for data and privacy protection. It should 
be recognized that the value for individuals 
and society of (re)using health data for re-
search purposes can be far greater than the 
residual risk. 
• Increase citizens’ trust by raising their 
awareness of the potential benefits of data 
sharing and being transparent on the reuse 
of health data. Harmonized awareness 
campaigns across Europe might contribute 
to generating the social and political mo-
mentum needed to make this a challenge 
for the whole of European society. In order 
to ensure adequate engagement and the 
necessary transparency, it could then be 
beneficial to notify citizens of all the results 
obtained in clinical-health research thanks 
to the contribution of the data they have 
made available to science. Also, as long as 
there is public trust in research, it is advisa-
ble to give a central role to universities and 
their researchers in the management of 
health data storage, quality and interoper-
ability, and transfers.
 

